Abstract 2326: LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner
Article 2016 en
Authors
TY
Takahiro Yamazaki
MV
Marie Vétizou
CF
Camila Flores
Abstract
1 min read
Abstract Intratumoral immunotherapies aim at reducing local immunosuppression as well as reinstating and enhancing systemic anticancer T cell functions without inducing side effects. LTX-315 is a first-in-class oncolytic peptide -based local immunotherapy that meets these criteria by inducing a type of malignant cell death that elicits anticancer immune responses. Here, we show that LTX-315 rapidly reprograms the tumour microenvironment by decreasing the local abundance of immunosuppressive Tregs and myeloid derived-suppressor cells and by increasing the frequency of polyfunctional TH1/TC1 cells with a concomitant raise in their expression of CTLA4 and a drop in PD-1 expression. Logically, in tumours that were resistant to intratumoural or systemic CTLA4 blockade, subsequent local inoculation of LTX-315 cured the animals or caused tumour regressions with abscopal effects(meaning that even malignant lesions that were established in the opposite flank and were not treated by LTX-315 responded to the therapy). This synergistic interaction between CTLA4 blockade and LTX-315 was reduced upon blockade of the β-chain of the interleukin-2 receptor (CD122) which is required for signalling in response to IL-2 and IL-15. This preclinical study provides a strong rationale for administering the oncolytic peptide LTX-315 to patients who are receiving treatment with the CTLA4 blocking antibody ipilimumab. Citation Format: Takahiro Yamazaki, Marie Vetizou, Camila Flores, Aurelien Marabelle, Baldur Sveinbjørnsson, Øystein Rekdal, Guido Kroemer, Laurence Zitvogel. LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2326.
Wei Xie, Laura Mondragón, Brynjar Mauseth, Yan Wang, Jonathan Pol, Sarah Lévesque, Heng Zhou, Takahiro Yamazaki, J. Johannes Eksteen, Laurence Zitvogel, Baldur Sveinbjørnsson, Øystein Rekdal, Oliver Kepp, Guido Guido Kroemer
Discussion(0)
No comments yet. Be the first to comment.